Ryan D Morrison

List of Publications by Year
in descending order

52 papers	1,317 citations	331670 21 h-index	377865 34 g-index
53 all docs	53 docs citations	53 times ranked	1776 citing authors

#	Article	IF	Citations
1	ML297 (VU0456810), the First Potent and Selective Activator of the GIRK Potassium Channel, Displays Antiepileptic Properties in Mice. ACS Chemical Neuroscience, 2013, 4, 1278-1286.	3.5	135
2	Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics. ACS Chemical Neuroscience, 2017, 8, 1570-1576.	3.5	100
3	The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 404-421.	2.5	95
4	Design, Synthesis, and Biological Evaluation of Halogenated N-(2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: Discovery of an Isoform-Selective Small Molecule Phospholipase D2 Inhibitor. Journal of Medicinal Chemistry, 2010, 53, 6706-6719.	6.4	92
5	Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. Journal of Medicinal Chemistry, 2015, 58, 7485-7500.	6.4	62
6	First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers. BMC Pharmacology & Toxicology, 2019, 20, 1.	2.4	44
7	Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism. Drug Metabolism and Disposition, 2013, 41, 1703-1714.	3.3	42
8	Targeting Selective Activation of M₁ for the Treatment of Alzheimerâ€™s Disease: Further Chemical Optimization and Pharmacological Characterization of the M₁ Positive Allosteric Modulator ML169. ACS Chemical Neuroscience, 2012, 3, 884-895.	3.5	41
9	VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2015, 356, 123-136.	2.5	41
10	Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu₃ NAMs. ACS Medicinal Chemistry Letters, 2017, 8, 925-930.	2.8	38
11	The Role of Aldehyde Oxidase and Xanthine Oxidase in the Biotransformation of a Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5. Drug Metabolism and Disposition, 2012, 40, 1834-1845.	3.3	36
12	Discovery of		

#	Article	IF	Citations
19	Assessment of Patient Medication Adherence, Medical Record Accuracy, and Medication Blood Concentrations for Prescription and Over-the-Counter Medications. JAMA Network Open, 2018, 1, e184196.	5.9	25
20	Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu2/mGlu3 NAMs. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2693-2698.	2.2	24
21	Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring. PLoS ONE, 2017, 12, e0185471.	2.5	23
22	Use of a novel rapid and resourceâ€efficient cassette dosing approach to determine the pharmacokinetics and CNS distribution of small molecule 7â€transmembrane receptor allosteric modulators in rat. Pharmacology Research and Perspectives, 2014, 2, e00077.	2.4	22
23	Discovery of a Highly Selective PLD2 Inhibitor (ML395): A New Probe with Improved Physiochemical Properties and Broadâ€Spectrum Antiviral Activity against Influenza Strains. ChemMedChem, 2014, 9, 2633-2637.	3.2	18
24	Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer. Scientific Reports, 2020, 10, 9805.	3.3	17
25	Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry. Laboratory Investigation, 2020, 100, 874-886.	3.7	17
26	Substituted 1-Phenyl-3-(pyridin-2-yl)urea Negative Allosteric Modulators of mGlu₅: Discovery of a New Tool Compound VU0463841 with Activity in Rat Models of Cocaine Addiction. ACS Chemical Neuroscience, 2013, 4, 1217-1228.	3.5	16
27	Evaluating the Disposition of a Mixed Aldehyde Oxidase/Cytochrome P450 Substrate in Rats with Attenuated P450 Activity. Drug Metabolism and Disposition, 2016, 44, 1296-1303.	3.3	15
28	Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain Models. ACS Chemical Neuroscience, 2019, 10, 1294-1299.	3.5	15
29	N-Acyl-Nâ€²-arylpiperazines as negative allosteric modulators of mGlu1: Identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3713-3718.	2.2	14
30	Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5035-5040.	2.2	13
31	Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators. ACS Chemical Neuroscience, 2017, 8, 1873-1879.	3.5	13
32	In vitro safety pharmacology evaluation of 2-hydroxybenzylamine acetate. Food and Chemical Toxicology, 2018, 121, 541-548.	3.6	13
33	Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3822-3825.	2.2	11
34	The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity. Prostaglandins and Other Lipid Mediators, 2019, 144, 106353.	1.9	11
35	VU0810464, a nonâ€urea G proteinâ€gated inwardly rectifying K⁺ (K_{ir}3/GIRK) channel activator, exhibits enhanced selectivity for neuronal K_{ir}3 channels and reduces stressâ€induced hyperthermia in mice. British Journal of Pharmacology, 2019, 176, 2238-2249.	5.4	10
36	Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5091-5096.	2.2	9

#	Article	IF	Citations
37	Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3307-3314.	2.2	9
38	Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys. ACS Chemical Neuroscience, 2016, 7, 1543-1551.	3.5	9
39	N-Alkylpyrido[1â€²,2â€²:1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1894-1900.	2.2	9
40	Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1067-1070.	2.2	8
41	Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4858-4866.	2.2	8
42	Managing Psychotropic Medications in Complex, Real-World Patients Using Comprehensive Therapeutic Drug Monitoring. ACS Chemical Neuroscience, 2017, 8, 1641-1644.	3.5	8
43	Synthesis and biological characterization of a series of novel diaryl amide M1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6923-6928.	2.2	7
44	Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1044-1048.	2.2	6
45	Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 37-41.	2.2	5
46	Medication Exposure in Highly Adherent Psychiatry Patients. ACS Chemical Neuroscience, 2018, 9, 555-562.	3.5	5
47	Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 47-50.	2.2	5
48	SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2224-2228.	2.2	4
49	Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2915-2919.	2.2	3
50	Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1679-1685.	2.2	2
51	Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. Journal of Clinical Pathology, 2022, 75, 636-642.	2.0	2
52	Supratherapeutic Psychotropic Drug Levels in the Emergency Department and Their Association with Delirium Duration: A Preliminary Study. Journal of the American Geriatrics Society, 2019, 67, 2387-2392.	2.6	1